A randomized, placebo-controlled clinical trial to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and exploratory clinical activity of NM26-2198 in healthy subjects and in patients with moderate-to-severe atopic dermatitis (AD)

What you commit to

• Study type: Interventional · Phase 1
• Participants enrolled: 14
• 9 sites in 2 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.

Sites (9)

Sites in registry order. Save your city in your profile to sort them by distance.